Helen A. Watson

Once-daily valacyclovir to reduce the risk of transmission of genital herpes*

Lawrence Corey, Jorma Paavonen, Gregory Mertz, 2004, The New England journal of medicine.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Rebecca M. Baker, Phuong Thi Tuyet Nguyen, Carol L. Eyler, 2021, The Lancet Infectious Diseases.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

A. Wald, O. Keene, L. Corey, 2004, The New England journal of medicine.

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.

P. Yates, F. Marty, D. Shortino, 2017, The Lancet. Respiratory medicine.

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

R. Levine, D. Rockey, H. Makhlouf, 2010, Gastroenterology.

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

R. Levine, D. Rockey, H. Makhlouf, 2010, Gastroenterology.

Lessons from resistance analysis in clinical trials of IV zanamivir

P. Yates, Helen A. Watson, Helen A Watson, 2023, Virus research.